Table 2.
Frequency of bothersome HIV symptoms by treatment and study visit in Study GS-US-380-1489 (treatment-naïve)
| Individuals reporting symptom, % | Baseline | Week 4 | Week 12 | Week 48 | ||||
|---|---|---|---|---|---|---|---|---|
| B/F/TAF (n = 311) |
ABC/DTG/3TC (n = 313) |
B/F/TAF (n = 313) |
ABC/DTG/3TC (n = 310) |
B/F/TAF (n = 307) |
ABC/DTG/3TC (n = 309) |
B/F/TAF (n = 293) |
ABC/DTG/3TC (n = 298) |
|
| Fatigue/loss of energy | 47.3 | 46.6 | 37.7 | 47.1 | 33.6 | 41.7 | 32.8 | 41.4 |
| Fevers/chills/sweats | 26.7 | 21.7 | 20.4 | 18.7 | 14.0 | 15.5 | 15.4 | 14.8 |
| Dizzy/lightheadedness | 21.3 | 17.7 | 17.6 | 23.5 | 15.0 | 17.6 | 13.0 | 21.5 |
| Pain/numbness/tingling in hands/feet | 20.3 | 16.0 | 14.7 | 16.8 | 16.4 | 17.5 | 19.1 | 19.6 |
| Trouble remembering | 22.8 | 18.0 | 20.1 | 19.0 | 23.8 | 20.4 | 20.8 | 21.5 |
| Nausea/vomiting | 8.4 | 8.0 | 13.7 | 23.9 | 7.5 | 15.6 | 9.6 | 12.4 |
| Diarrhea/loose bowels | 20.9 | 18.9 | 20.8 | 21.3 | 15.6 | 18.8 | 11.6 | 14.8 |
| Sad/down/depressed | 41.9 | 36.5 | 31.9 | 35.5 | 33.2 | 32.4 | 27.6 | 31.3 |
| Nervous/anxious | 45.3 | 38.0 | 31.9 | 32.9 | 27.8 | 30.1 | 28.8 | 30.2 |
| Difficulty sleeping | 35.8 | 39.6 | 32.9 | 35.8 | 29.1 | 38.2 | 29.4 | 36.2 |
| Skin problems/rash/itching | 27.3 | 28.5 | 21.7 | 25.8 | 19.5 | 22.3 | 20.8 | 22.1 |
| Coughing/trouble breathing | 15.4 | 15.4 | 13.4 | 14.0 | 14.4 | 13.9 | 12.7 | 14.1 |
| Headaches | 21.9 | 21.2 | 20.8 | 22.7 | 18.6 | 21.0 | 13.0 | 22.9 |
| Loss of appetite | 16.8 | 14.8 | 13.4 | 16.6 | 10.5 | 18.1 | 9.6 | 12.8 |
| Bloating/pain/gas in stomach | 19.7 | 21.0 | 24.4 | 24.4 | 20.3 | 22.0 | 18.5 | 25.3 |
| Muscle aches/joint pain | 27.1 | 28.3 | 19.2 | 21.1 | 23.6 | 22.3 | 21.6 | 25.3 |
| Problems with sex | 26.1 | 26.4 | 18.6 | 17.2 | 18.0 | 16.2 | 17.5 | 18.9 |
| Changes in body composition | 17.4 | 15.2 | 14.7 | 12.3 | 17.4 | 15.2 | 19.5 | 22.9 |
| Weight loss/wasting | 18.3 | 11.3 | 9.6 | 9.4 | 7.2 | 11.4 | 11.6 | 11.4 |
| Hair loss/changes | 10.3 | 12.9 | 6.7 | 9.4 | 6.9 | 8.4 | 5.5 | 8.8 |
n is the number of participants with response for at least one symptom
Bold characters are for significantly different percentages between treatment groups (p < 0.05), p value is calculated from the unadjusted logistic regression model
ABC/DTG/3TC co-formulated abacavir, dolutegravir, and lamivudine, B/F/TAF co-formulated bictegravir, emtricitabine, and tenofovir alafenamide